Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.75 USD
Change Today +0.1485 / 5.71%
Volume 141.3K
As of 1:09 PM 11/25/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

4 Maguire Road

Lexington, MA 02421

United States

Phone: 617-503-6500

Fax: 617-503-6501

Curis, Inc., a biotechnology company, focuses on developing and commercializing drug candidates for the treatment of human cancers. CUDC-907 The company’s most advanced drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC), and phosphatidylinositol-3-kinase (PI3K) enzymes, which has completed the dose escalation stage of a first-in-man Phase 1 clinical study in patients with relapsed, refractory lymphoma or multiple myeloma. In addition, the company entered into a multi-year collaboration agreement focused on immuno-oncology and selected precision oncology targets with Aurigene Discovery Technologies Limited (Aurigene), a specialized, discovery stage biotechnology company and wholly-owned subsidiary of Dr. Reddy’s Laboratories. In 2013, the company initiated a Phase 1 clinical study of CUDC-907 in patients with relapsed or refractory lymphomas or multiple myeloma. In 2014, the company established the recommended Phase 2 dose and schedules of administration for further development of CUDC-907, and initiated enrollment of patients primarily with diffuse large B-cell lymphoma (DLBCL) or multiple myeloma in the expansion stage of the Phase 1 study. Development of CUDC-907 in hematological malignancies is partially supported under collaboration with The Leukemia & Lymphoma Society (LLS). In 2014, the company initiated a separate Phase 1 trial to investigate CUDC-907 in patients with advanced solid tumors, including those with hormone receptor positive breast cancer or with NUT midline carcinoma. CUDC-427 The company’s proprietary pipeline also includes CUDC-427, an orally-available, small molecule antagonist of inhibitor of apoptosis (IAP) proteins, which has completed dose escalation in a Phase 1 clinical trial in patients with solid tumors or lymphoma. In 2012, the company licensed from Genentech Inc. (Genentech) the exclusive, worldwide rights for the development and commercialization of CUDC-427. Under the terms of the license agreement, the company has the sole right and responsibility for all research, development, manufacturing and commercialization activities related to CUDC-427. Other The company also regained rights to its Heat Shock Protein 90 (HSP90), inhibitor Debio 0932 from Debiopharm International S.A. (Debiopharm). The company has redesignated this drug candidate as CUDC-305 and is in the process of evaluating initiating clinical studies with CUDC-305 in 2015. The company’s collaborators F. Hoffmann-La Roche Ltd (Roche) and Genentech are commercializing Erivedge (vismodegib), a first-in-class orally-administered small molecule Hedgehog pathway inhibitor, in advanced basal cell carcinoma (BCC). Erivedge Erivedge is the United States Food and Drug Administration (FDA) approved medicine for treatment of metastatic or locally advanced basal cell carcinoma (BCC), and is being developed and commercialized by Roche and Genentech under a collaboration agreement between the company and Genentech. In 2012, the FDA approved Erivedge for treatment of adults with BCC that has spread to other parts of the body, or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation, collectively considered as advanced BCC. Intellectual Property In the U.S., as of December 31, 2014, the company had 94 issued or allowed patents expiring on various dates between 2015 and 2033, as well as various pending patent applications. Research and Development As of December 31, 2014, the company incurred expenses of $13,659,000 on research and development activities. History Curis, Inc. was founded in 2000 as a Delaware corporation.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CRIS:US $2.75 USD +0.1485

CRIS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $2.34 USD 0.00
CTI BioPharma Corp $1.22 USD +0.04
Cytokinetics Inc $12.04 USD -0.07
MELA Sciences Inc $1.20 USD 0.00
Navidea Biopharmaceuticals Inc $1.50 USD 0.0001
View Industry Companies

Industry Analysis


Industry Average

Valuation CRIS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 42.4x
Price/Book 4.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 27.1x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact CURIS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at